Alzheimer’s Drug Appears to Slow Disease’s Progress in ‘Historic’ Trial
The finding has raised hopes that scientists could eventually cure dementia.

Getty
Get the Beast Digest newsletter delivered straight to your inbox
By clicking “SIGN UP” you agree to our Terms of Use and Privacy Policy.
After decades of disappointments, an experimental drug has been shown to slow the progress of Alzheimer’s disease for the first time. Lecanemab attacks clumps of protein called amyloid which are thought to be a central component of the most common form of dementia. Trial data published at a conference in San Francisco showed the drug slowed patients’ mental decline by around a quarter over 18 months of treatment. Despite Lacanemab only having a slight effect and only working on patients in the early stages of Alzheimer's, the results have been heralded as a major breakthrough. Professor John Hardy, a geneticist and molecular biologist who was one of the leading researchers to support research targeting amyloid 30 years ago, said the drug breakthrough was “historic,” while Alzheimer’s Research UK called the findings “momentous.”
Unlock a year of full access to The Daily Beast for $35.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Looks like you already have a subscription!
- Account (completed)
- Payment (completed)
- Confirmation (completed)
You're all set!
Thanks for subscribing.
- 1Account
- 2Payment
- 3Confirmation
Sign in or create an account
Register below to read this article for free or subscribe
to unlock unlimited access to The Daily Beast.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Already have an account? Sign In
Looks like you already have a subscription!
- Account (completed)
- Payment (completed)
- Confirmation (completed)
You're all set!
Thanks for subscribing.
- 1Account
- 2Payment
- 3Confirmation